People who cycle to work have a lower risk of dying, a New Zealand study has found.

This is a continuing profile series on the directors of the Department of Energy (DOE) Office of Science user facilities. These scientists lead a variety of research institutions that provide researchers with the most advanced tools of modern science including accelerators, colliders, supercomputers, light sources and neutron sources, as well as facilities for studying the nano world, the environment, and the atmosphere.

Marivi Fernandez-Serra is a professor in the Department of Physics and Astronomy at Stony Brook University.

Most nuclear data measurements are performed at accelerators large enough to occupy a geologic formation a kilometer wide. But a portable device that can reveal the composition of materials quickly on-site would greatly benefit cases such as in archaeology and nuclear arms treaty verification. Research published this week in AIP Advances used computational simulations to show that with the right geometric adjustments, it is possible to perform accurate neutron resonance transmission analysis in a device just 5 meters long.

The production of formate from CO2 is considered an attractive strategy for the long-term storage of solar renewable energy in chemical form.

Nearly everyone on Earth is familiar with corn. Literally. Around the world, each person eats an average of 70 pounds of the grain each year, with even more grown for animal feed and biofuel.

Examining the factors that affect the number of females being harvested during the bear hunting season will help Pennsylvania wildlife officials manage population.

Owlet started learning about Beethoven in music class at school just before March break. She ran to meet me at the school gate and this is the conversation we had: OWLET: Mummy, do you know Beethoven? ME: Not personally, but I know his music. OWLET: Why not? ME: Well, honey, he’s dead. OWLET: WHAT. He […]

Owlet has decided that violin lessons are interesting, and so she’s doing a couple of private ones with her violin teacher from camp in the afternoons. From what I saw yesterday, she works better one on one than in a group setting, which doesn’t surprise me at all, really. The fingerboard popped off her violin […]

I live in Stockport, just outside Manchester. It's 10 minutes by train away, but I’m not sure if the trains are running – and in any case I’ve not actually been in my office in Central Manchester since February 20.
That got complex. I was in Iraq for work and came home in early March with a virus. Just not that virus but they wouldn’t test me because Iraq (you know, right next door to Iran) wasn’t on the WHO list.
So. Context. We live in a suburban semi-detatched house with a garden (big for Edgeley). There’s me. Matt the husband.…

The beauty of slow TV, says Spencer Stoner, is that it’s different things to different people – a travelogue, an immersive experience, an awesome screensaver. After the success of last year’s Go South, Stoner has spent a month at sea filming Go Further South, a 12-hour journey from Bluff to Antarctica.
Not to put too fine a point on it, but Go Further South is perfect for self-isolation.
It’s kind-of an unhappy accident. I’ve been in the final stage of editing and every day I feel like I’m sailing through the Ross Sea in Antarctica and it’s cool to think that…

The closing panel in The Listening Lounge at February's Splore festival was a fairly ambitious one, I wasn't sure whether it was going to work and I knew I was going to depend on my panelists – a psychologist, a brilliant young Zimbabwean New Zealander, an evangelical pastor and a campaign expert – to make it work.
I'm never really sure after these discussions what's actually happened – I've spent the whole time in the moment. But re-reading the transcript (thank you to Emma Hart for that), I felt good about it.
I also felt that the subtitle: "How do we all move…

For obvious reasons, there has been a lot of attention paid to work going into developing vaccines that could prevent Covid-19 infection, and drugs that could treat it. In particular, there has been some excitement about new animal trial data for remdesivir, a drug developed by Gilead Sciences. Gilead's share price rose nearly 10% on the day the trial data were announced.
It will be some time yet before the safety and efficacy of remdesvir is established, if ever (it's worth noting that it was tried, unsuccessfully, as a treatment for Ebola). And since I started work on this post…

Regular readers will know that I've been hanging out for the "market allocation" parts of the proposed Cannabis Legalisation and Control Bill, which will be the subject of a referendum this year.
While most media outlets ran inane stories last year on how many joints 14 grams added up to, it was clear to anyone who took the subject seriously that the questions of who would get to produce and sell cannabis and how licences would be awarded were vastly more important. And we've had to wait for answers to those.
Well, they're here. And it's very good news. From…